Wall Street Journal

CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure

SYDNEY—Vaccine and blood-products company CSL on Tuesday unveiled a sweeping corporate restructure that will include spinning off its flu-vaccine unit Seqirus and cutting up to 15% of its staff.
MarketWatch

CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure -- Update

SYDNEY--Vaccine and blood-products company CSL on Tuesday unveiled a sweeping corporate restructure that will include spinning off its flu-vaccine unit Seqirus and cutting up to 15% of its staff.